-

Orthofix Announces Election of Jason Hannon to Board of Directors

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc., (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced that Jason M. Hannon has been elected by its shareholders to the Company’s Board of Directors. A seasoned medical device executive, Hannon is currently the Chief Executive Officer of Mainstay Medical International plc, a global company headquartered in Ireland focused on bringing to market the ReActiv8, an implantable restorative neurostimulation system to treat disabling chronic low back pain.

“We are very pleased that Jason is joining the Orthofix Board of Directors,” said Ron Matricaria, Chairman of the Board. “We feel his broad experience in the medical device industry and specifically his expertise in Spine will bring valuable industry insights to the Company.”

Hannon has also served as President and Chief Operating Officer of NuVasive, Inc. Over the course of 12 years at NuVasive, he held various roles of increasing responsibility, including as Executive Vice President, International; and Executive Vice President, Corporate Development; and General Counsel. During Hannon’s tenure, he led initiatives to expand product launches, revamp the commercialization process for global development and structured multiple strategic partnerships and acquisitions.

Hannon has a JD degree from Stanford University Law School and a BA degree from the University of California, Berkeley.

About Orthofix

Orthofix Medical Inc. is a global medical device company focused on musculoskeletal products and therapies. The Company’s mission is to improve patients' lives by providing superior reconstruction and regenerative musculoskeletal solutions to physicians worldwide. Headquartered in Lewisville, Texas, Orthofix’s spine and orthopedic extremities products are distributed in more than 70 countries via the Company's sales representatives and distributors. For more information, please visit www.orthofix.com.

Contacts

Mark Quick
Investor Relations
214-937-2924
markquick@orthofix.com

Denise Landry
Media Relations
214-937-2529
deniselandry@orthofix.com

Orthofix Medical Inc.

NASDAQ:OFIX

Release Summary
Orthofix Medical Inc., elects medical device executive Jason Hannon to the Company’s Board of Directors.
Release Versions

Contacts

Mark Quick
Investor Relations
214-937-2924
markquick@orthofix.com

Denise Landry
Media Relations
214-937-2529
deniselandry@orthofix.com

Social Media Profiles
More News From Orthofix Medical Inc.

Orthofix to Participate in Upcoming Investor Conferences

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Orthofix will participate in the following investor conferences: Goldman Sachs 47th Annual Global Healthcare Conference - Miami Beach, June 8, 2026, Fireside Chat Time: 8:40 am Eastern Time Truist Securities MedTech Conference - Boston, June 16, 2026, 1x1 Meetings Only Interested parties can access the live and archived webcast of the Goldman Sachs fireside...

Orthofix Expands Pediatric Limb Reconstruction Portfolio with New FITBONE™ Innovation at POSNA 2026 Annual Meeting

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced new pediatric limb reconstruction innovations that expand treatment options for pediatric and small stature patients. The Company will highlight these advances at the Pediatric Orthopedic Society of North America (POSNA) 2026 Annual Meeting, which takes place May 6-8, 2026, at the Rosen Shingle Creek Hotel in Orlando, Florida. At POSNA 2026, Orthofix will showcas...

Orthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2026, reflecting steady execution following recent spine commercial channel actions. Based on first-quarter performance, the Company reaffirmed its full-year 2026 financial guidance. All pro forma measures contained within this release exclude the impact of the Company’s decision to discontinue its M6™ pr...
Back to Newsroom